Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in MEDNAX Inc (NYSE:MD) by 74.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,891 shares of the company’s stock after selling 14,141 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in MEDNAX were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Prudential Financial Inc. lifted its position in shares of MEDNAX by 976.9% in the third quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock worth $27,642,000 after purchasing an additional 581,527 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of MEDNAX in the third quarter worth approximately $695,000. Point72 Asset Management L.P. lifted its position in shares of MEDNAX by 71.7% in the third quarter. Point72 Asset Management L.P. now owns 132,700 shares of the company’s stock worth $5,722,000 after purchasing an additional 55,400 shares in the last quarter. Nomura Holdings Inc. purchased a new stake in shares of MEDNAX in the second quarter worth approximately $347,000. Finally, Advisor Group Inc. lifted its position in shares of MEDNAX by 41.9% in the third quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock worth $359,000 after purchasing an additional 2,468 shares in the last quarter. 95.12% of the stock is owned by institutional investors and hedge funds.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.
MEDNAX Inc (MD) opened at $56.61 on Tuesday. MEDNAX Inc has a 52-week low of $40.56 and a 52-week high of $72.13. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. The firm has a market cap of $5,309.77, a P/E ratio of 16.41, a P/E/G ratio of 1.40 and a beta of 0.31.
MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The company had revenue of $910.82 million for the quarter, compared to the consensus estimate of $884.55 million. During the same quarter last year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. equities analysts expect that MEDNAX Inc will post 4.04 EPS for the current year.
MD has been the topic of several recent research reports. KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a research report on Wednesday, November 1st. Jefferies Group reaffirmed a “hold” rating and set a $44.00 price objective on shares of MEDNAX in a research report on Friday, November 3rd. Robert W. Baird raised their price objective on shares of MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research report on Friday, November 3rd. Citigroup cut their price objective on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Finally, Piper Jaffray Companies initiated coverage on shares of MEDNAX in a research report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $54.92.
TRADEMARK VIOLATION WARNING: “MEDNAX Inc (MD) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/20/mednax-inc-md-shares-sold-by-zurcher-kantonalbank-zurich-cantonalbank.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.